# OnCo record defibrotide (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/defibrotide/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "defibrotide" ;
  schema:name "Defibrotide"@en ;
  schema:description "Defibrotide (Defitelio) is the only approved treatment for hepatic veno-occlusive disease, a life-threatening liver complication of high-dose chemotherapy before stem cell transplant, in patients whose kidneys or lungs are also failing."@en ;
  schema:url <https://onco.cc/drugs/defibrotide/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Defibrotide> ;
  schema:citation <https://doi.org/10.1182/blood-2015-10-676924>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c3db989-d7ad-41ed-9ebf-698dcf6c24ec>, <https://www.cancer.gov/about-cancer/treatment/drugs/defibrotide-sodium>, <https://www.ema.europa.eu/en/medicines/human/EPAR/defitelio> ;
  onco:status "approved" ;
  onco:tag "nci-list", "supportive" ;
  onco:modality "Polydisperse oligonucleotide mixture (endothelial protectant)" ;
  schema:alternateName "Defitelio" ;
  onco:approval "US 2016: Hepatic veno-occlusive disease with renal or pulmonary dysfunction after HSCT, adults and children", "EU 2013: Severe hepatic veno-occlusive disease after HSCT in patients over one month (Defitelio)" ;
  onco:technologies <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/> ;
  onco:companies <https://onco.cc/companies/jazz/> ;
  onco:trials <https://onco.cc/trials/study-2005-01/> .